Autres langues Atara Biotherapeutics, Inc.

Actions

ATRA

US0465131078

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,69 ^USD	-1,40%		+4,39%	+34,56%

01/04	ATARA BIOTHERAPEUTICS, INC. : Stifel Nicolaus n'est pas inspiré par le dossier	ZM
29/03	Eric Dobmeier ne se représentera pas au Conseil d'administration d'Atara Biotherapeutics, Inc.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	05/04
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	29/03
Atara Biotherapeutics: Q4 Earnings Snapshot	28/03
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress	28/03
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M	28/03
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
North American Morning Briefing : Stocks Edge -2-	27/03
North American Morning Briefing : Markets on Hold -2-	20/03
North American Morning Briefing : Stock Futures -2-	13/03
Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy	29/02
Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application	29/02
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy	29/02
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference	28/02
Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis	14/02
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis	14/02
Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis	14/02
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology	01/02
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology	01/02
Latest Buzz on The Street: Noteworthy Developments at DYAI, ELEV, ATRA, ESPR, KAVL	17/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Atara Biotherapeutics, Inc.

Actions

ATRA

US0465131078

Autres langues

Filtres